Sources said the SEC has recommended the EUA with certain conditions. However, the final nod will be given by the Drugs Controller General of India (DCGI), which is also likely to come today itself.
Once the approval is in place, the vaccination process is likely to start in another 7-10 days, senior officials said.
The UK’s regulator Medicines and Health Products Regulatory Authority (MHRA) had approved the Oxford-AstraZeneca Covid vaccine – called Covishield in India – for emergency use on December 30.
As earlier reported by TOI, around 96,000 vaccinators have been trained for the Covid vaccination programme that aims to cover 30 crore priority population by July.
SII has said that it has stockpiled nearly 50 million doses of Covishield and adding more to it every week.
While exports are yet to begin, India is likely to receive most of these stocks during the initial months.
A nationwide dry run to assess the preparedness for the vaccination process is scheduled on January 2.
The dry run will be conducted in all state capitals and in at least 3 session sites. Some states will also carry out dry runs in districts that are situated in difficult terrains or have poor logistical support.
The SEC has not yet taken any decision on applications from Bharat Biotech and Pfizer seeking EUA for their respective candidates.
Covishield can be stored in fridge at 2-8 degree temperatures, making it a preferred option for India as against jabs developed by Pfizer and Moderna that require ultra-cold storage capacity.